Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) EBITDA Margin (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed EBITDA Margin for 7 consecutive years, with 1021.71% as the latest value for Q1 2025.

  • Quarterly EBITDA Margin rose 136402.0% to 1021.71% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 286.8% through Dec 2025, down 4163.0% year-over-year, with the annual reading at 286.8% for FY2025, 4163.0% down from the prior year.
  • EBITDA Margin for Q1 2025 was 1021.71% at Whitehawk Therapeutics, up from 252.74% in the prior quarter.
  • The five-year high for EBITDA Margin was 1021.71% in Q1 2025, with the low at 3405.83% in Q1 2021.
  • Average EBITDA Margin over 5 years is 421.8%, with a median of 266.48% recorded in 2022.
  • Peak annual rise in EBITDA Margin hit 280518bps in 2022, while the deepest fall reached -14765bps in 2022.
  • Over 5 years, EBITDA Margin stood at 118.84% in 2021, then tumbled by -124bps to 266.48% in 2022, then grew by 4bps to 256.5% in 2023, then increased by 1bps to 252.74% in 2024, then surged by 504bps to 1021.71% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 1021.71%, 252.74%, and 173.04% for Q1 2025, Q4 2024, and Q3 2024 respectively.